Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations

The RAS/RAF and PI3K/Akt pathways play a key regulatory role in cancer and are often hit by oncogenic mutations. Despite molecular targeting, the long-term success of monotherapy is often hampered by de novo or acquired resistance. In the case of concurrent mutations in both pathways, horizontal com...

Descripción completa

Detalles Bibliográficos
Autores principales: Rittler, Dominika, Molnár, Eszter, Baranyi, Marcell, Garay, Tamás, Hegedűs, Luca, Aigner, Clemens, Tóvári, József, Tímár, József, Hegedűs, Balázs
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589607/
https://www.ncbi.nlm.nih.gov/pubmed/33081092
http://dx.doi.org/10.3390/ijms21207649

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589607/
https://www.ncbi.nlm.nih.gov/pubmed/33081092
http://dx.doi.org/10.3390/ijms21207649

Ejemplares similares